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4/6 or worse CBUs were used. API pts were more often
transplanted with an HLA mismatched source when the
source is also race/ethnic mismatched.
Conclusion: This study shows that AFA, API, CAU, and HIS
pts, transplanted in the past 5 years, most utilized a race/
matched donor. From 2008 to present, greater than 70% of
donors and greater than 50% of CBU transplants were race/
ethnic matched between the pt and cell source. In addition,
better HLA matching was observed when the pt and cell
source were matched for race/ethnicity.15
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Haploidentical hematopoietic stem cell transplantation us-
ing T-cell depleted grafts (haploHSCT) is an option for pedi-
atric patients with high-risk hematological malignancies
lacking an HLA-identical donor. Since December 2006 to
September 2013; 55 children underwent an haploHSCT using
CD3+/CD19+ depletion for graft manipulation. Eleven pa-
tients were in 1st CR, 22 in 2nd CR and 22were in>2nd CR at
time of transplantation. The conditionig regimen consisted of
30 mg/m2/d of i.v. ﬂudarabine on days -6 to -2, 3.2-4.8 mg/
kg/day of i.v. busulfan on days -6 and -4 and 5 mg/kg/day of
i.v. thiotepa on days -3 to -2. PBPC were mobilized and
collected in the standard manner. GvHD prophylaxis
included CsA 3mg/kg/day from day -1. Allografts contained a
median of 5.75 x106 CD34 cells/kg and 1.0 x 104 CD3 cells/kg.
Median times to neutrophil and platelet recovery were 13
and 10 days, respectively. The probability of aGvHD and
cGvHD were 135% and 3110% respectively. NRM was
145% by day +100 and 216% by 2 years after transplant.
Cause of dead were relapse in 9 cases, severe viral infections
in 7 and graft failure in 2. The probability of relapse was
298%. With a median follow-up of 24 months, the proba-
bility of DFS was 558%. On a multivariate analysis the fac-
tors that positive impact on DFS were age below 12 years
(HR;0.26, 95%CI: 0.09-0.79 p<0.009) and cGvHD (HR;0.68,
95%CI: 0.01-0.53 p<0.01). Our results suggest that hap-
loidentical donors are a good option for pediatric patients
with high-risk hematological malignancies who need an
allogeneic transplantation. Graft manipulation resulted on
low incidence of severe aGvHD. DFS was better for patients
with cGvHD mainly due to lower relapse incidence. Severe
viral infections is a relevant problem in the early phase after
transplantation.16
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Background: Telomeres are long nucleotide repeats and an
associated protein complex at chromosome ends essential
for chromosomal stability. They shorten with every cell di-
vision and thus are a marker of cellular replicative capacity.
We hypothesized that telomere length may be a predictive
marker for outcomes after hematopoietic cell trans-
plantation (HCT).
Method: We used quantitative PCR (qPCR) to measure pre-
transplant relative telomere length (RTL) in blood DNA of 342
young recipients (median age¼14 yr; range¼0.5e39) and
their matched unrelated donors (median age¼36 yr;
range¼19-61). HCTs were performed for marrow failure
syndromes between 1989 and 2007 and reported to the
Center for International Blood and Marrow Transplant
Research (CIBMTR), and the National MarrowDonor Program
(NMDP). The log-rank test was used to compare survival
across RTL categories. For multivariable models, we used Cox
proportional hazard models and calculated hazard ratios
(HR) and 95% conﬁdence intervals (CI) comparing outcome
across RTL categories.
Results: Patients were followed for up to 20 years
(median¼6.3 years; range¼0.5e20.7), with an overall sur-
vival (OS) probability at 3 years of 49% (44-55). There were
243 (71%) with severe aplastic anemia, 87 (25%) with Fanconi
anemia, and 12 (4%) with Diamond Blackfan anemia. Pre-
transplant RTL in the recipients was not associated with
post-transplant outcomes, including OS (3-year survival
probability¼51% and 46%, in RTL 25% percentile and <25th
percentile-for age, respectively; p¼0.76); acute (p¼0.53 at
100 days) or chronic GVHD (p¼0.99 at 1 year) and neutrophil
engraftment (p¼0.48). Pre-transplant donor RTL was a sig-
niﬁcant predictor for OS after HCT, with longer donor telo-
mere length associated with improved survival (3 year OS
59%, 49%, and 38%, in the longest, intermediate, and shortest
tertiles, respectively; p¼0.006). No association between
donor RTL and either acute or chronic GVHD or engraftment
was observed. Donor RTL was correlated with age (R2¼0.12,
p<0.0001), but after adjusting for donor age and factors
known to inﬂuence patient survival after HCT (such as prior
treatment and time between diagnosis and transplant),
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recipient survival (HR¼0.63, 95% CI¼0.45-0.87, p¼0.006 for
longest tertile compared to the intermediate and shortest
tertiles)(ﬁg). There was no signiﬁcant interaction between
donor RTL and the patient’s underlying disease. Results were
similar when the analysis was limited to the severe aplastic
anemia group.
Conclusions: Our data suggest that longer donor telomere
lengths are signiﬁcantly associated with improved OS after
HCT for marrow failure syndromes, independent of donor
age. Additional studies of post-HCT donor telomere
dynamics are required to further explain this observation.17
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Reduced intensity conditioning (RIC) HSCT is a potentially
curative therapy for Myeloﬁbrosis (MF), but graft failure is a
major cause of treatment failure. We evaluated the outcomes
and risk factors for graft failure and survival in patients un-
dergoing RIC HSCT. We performed a retrospective review of
all patients receiving a ﬁrst RIC HSCT for MF at Dana Farber
Cancer Institute/Brigham and Women’s Hospital between
January 1, 2000 and December 31, 2012. Primary graft failure
(PGF) was deﬁned as the inability to achieve an ANC greater
than 0.5x109/L for three consecutive days. Secondary failure
was deﬁned as achievement of WBC engraftment with sub-
sequent decline in chimerism to <50%, or need for donor
lymphocyte infusion (DLI) or second HSCT. An event was
deﬁned as primary or secondary graft failure or relapse.
Median age of the cohort (n¼ 40) was 62 years (44-73). The
RIC regimens included ﬂudarabine/IV busulfan 3.2 mg/kg
(Flu/Bu1) (24), ﬂudarabine/IV busulfan 6.4 mg/kg (Flu/Bu2)
(15), or ﬂudarabine/melphalan (1). A majority of patients
received tacrolimus, sirolimus and methotrexate (24) for
GVHD prophylaxis. Nine patients received ATG as part of the
conditioning. All received PBSC except one who received a
dUCBT. Thirty-four patients received 10/10 matched trans-
plants from related or unrelated donors. Eighteen patientsFigure 1.(45%) experienced graft failure including one patient with
PGF. 22.5% of all patients had D30 and 35% had D100
chimerism<50%. Unplanned DLI were needed in 12/40 (30%)
patients. Seven patients (17.5%) ultimately needed a second
transplant for persistent disease and/or poor chimerism.
Grade II-IV acute GVHD incidence at D180 was 18%. Chronic
GVHD incidence at 2 years was 27%. With median follow-up
of 28months, the 2-year EFS and OSwere 29% and 51%. Based
on univariate analysis, use of ATG (p¼0.03), female recipient
gender (p¼0.03), andWBC<5K at transplant (p¼0.016) were
associated with longer EFS, while predictors for superior OS
were absence of circulating blasts (p¼0.004), low platelet
count (p¼0.011) and unrelated donor (p¼0.03). DIPSS score
and spleen size did not predict for EFS or OS. There was a
trend toward improved 2-year OS in patients who received
Flu/Bu2 compared to those who received Flu/Bu1 (53% vs.
21%, p¼ 0.10). We developed a prognostic score based on
factors found to be signiﬁcant on univariate analysis. Based
on this composite score incorporating 1 point for platelet
count>100x109/L, blast count>5%, and non-MUD donor, the
2-year EFS was 49% for score<¼1 and 12% for score>¼2
(p¼0.0017); the 2-year OS was 67% for score<¼1 and 21% for
score>¼2 (p¼0.0003) (Figure 1). RIC HSCT using low dose
Flu/Bu is associated with a high incidence of mixed chime-
rism and late graft failure necessitating frequent unplanned
DLI or second HSCT. The incidence of graft failure may be
mitigated by increasing the intensity of the conditioning
regimen or addition of ATG.18
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Measurement of minimal residual disease (MRD) and the
analysis of chimerism after hematopoietic stem cell trans-
plantation (HSCT) have been used for the detection of
impending relapse. Here, we present the clinical relevance of
both methods. We investigated MRD in 135 consecutive
children with ALL (n¼62), AML (n¼42), MDS (n¼24), or CML
(n¼7) who underwent HSCT. The Wilms’ tumor gene (WT1)
expression was used for the detection of MRD because WT1
is overexpressed in the vast majority of patients with leu-
kemia. For the present study, we investigated if the MRD
status prior to HSCT has any prognostic value. We observed a
signiﬁcantly reduced cumulative incidence of relapse (7%
versus 48%; p<0.001) and a signiﬁcantly increased 5-year
event-free survival (84% versus 35%; p<0.001) in patients
who were MRD negative before transplantation. All 99 pa-
tients who were continuously MRD negative remained in
complete remission at a median of 2432 days after HSCT. In
contrast, all 34 patients who suffered from hematological
relapse after a median of 167 days presented with high levels
of WT1 gene expression (p<0.001). In 21 patients, we
observed an increase ofWT1 expression levels at a median of
31 days before hematological relapse. In 17 of these 21 pa-
tients, DNA was available at the time of increase of WT1
expression level to perform analysis of hematopoietic
chimerism using a quantitative short-tandem-repeat PCR.
Interestingly, only 9 of the 17 patients (53%) showed a mixed
chimerism, whereas 8 of the 17 patients (47%) revealed a
complete donor chimerism. In the remaining 13 patients
with relapse, no increase of WT1 expression levels could be
